Vemurafenib in non-small-cell lung cancer patients with BRAF

Autor: J, Mazieres, C, Cropet, L, Montané, F, Barlesi, P J, Souquet, X, Quantin, C, Dubos-Arvis, J, Otto, L, Favier, V, Avrillon, J, Cadranel, D, Moro-Sibilot, I, Monnet, V, Westeel, J, Le Treut, E, Brain, J, Trédaniel, M, Jaffro, S, Collot, G R, Ferretti, C, Tiffon, C, Mahier-Ait Oukhatar, J Y, Blay

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 31(2)

BRAF mutations occurring in 1%-5% of patients with non-small-cell lung cancer (NSCLC) are therapeutic targets for these cancers but the impact of the exact mutation on clinical activity is unclear. The French National Cancer Institute (INCA) launched

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::022cc35e141fe594fad5da762e1baa83
https://pubmed.ncbi.nlm.nih.gov/31959346

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Autor: Marcelo Garrido, Paul Baas, Gregory M. Lubiniecki, A. Samkari, C. Dubos Arvis, Erin Jensen, Dong Wook Kim, Margarita Majem, Mary J. Fidler, J-Y. Han, Yue Shentu, G. De Castro, Jose Luis Perez-Gracia, Veerle Surmont, Kenneth Emancipator, Myung-Ju Ahn, Enriqueta Felip, Julian R. Molina, Roy S. Herbst, Joo Hang Kim, Edward B. Garon

Publikováno v: ANNALS OF ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Dadun. Depósito Académico Digital de la Universidad de Navarra

Background In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC). A prespecified exploratory analysis compared outcomes i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84f7f7658488a912b530fdef5f9bb75d
https://hdl.handle.net/10171/62022

[Malignant mesothelioma and constitutional BAP1 gene mutations]

Autor: Z, Neviere, P, Berthet, F, Polycarpe, C, Dubos-Arvis, P, Dô, R, Gervais

Publikováno v: Revue des maladies respiratoires. 36(2)

Malignant mesothelioma is a rare tumour, usually the result of asbestos exposure. Several cases of familial aggregation have been reported and recently shown to be associated with constitutional mutations of the BAP1 gene. BAP1 is a deubiquitinating

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::81e45ade31d8c1222b66cbbaae17d6ec
https://pubmed.ncbi.nlm.nih.gov/30686559

Activité de l’osimertinib dans les méningites carcinomateuses des cancers non à petites cellules (CPNPC) avec mutation activatrice de l’EGFR ayant déjà bénéficié d’un traitement par inhibiteur tyrosine-kinase (TKI) de l’EGFR

Autor: H. Janicot, K. Saboundji, Florian Guisier, C. Dubos Arvis, G. Francois, L. Odier, Radj Gervais, Maurice Pérol, P.A. Renault, Christos Chouaid, Marie Marcq, Jean-Bernard Auliac

Publikováno v: Revue des Maladies Respiratoires. 35:A58-A59

Introduction La survenue d’une meningite carcinomateuse est un evenement rare et de mauvais pronostic dans la progression des CPNPC EGFR mutes. L’osimertinib, TKI de 3e generation de l’EGFR, a demontre un meilleur passage de la barriere hemato-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a15855689f765aadaa472fda283a1899
https://doi.org/10.1016/j.rmr.2017.10.121

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.